Skip to Main Content
Contribute Try STAT+ Today

As the year winds down, STAT reporters are taking a look at the stories they’re most eager to track in 2018. Find all our “three to watch” series here

The pharmaceutical industry may be flush with cash and generating some genuine breakthrough treatments, but drug makers will remain embattled in the coming year.

Pharma’s perpetual race for profits and reliance on the U.S. as its biggest customer are certain to cause tensions as Americans struggle with pocketbook anxiety over high drug prices. Similarly, various moves to fend off competition will continue to generate scrutiny. And you can be certain industry hiring and investment will be closely tracked now that drug makers are getting a windfall from the new tax bill.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.